RS61193B1 - So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje - Google Patents
So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanjeInfo
- Publication number
- RS61193B1 RS61193B1 RS20201514A RSP20201514A RS61193B1 RS 61193 B1 RS61193 B1 RS 61193B1 RS 20201514 A RS20201514 A RS 20201514A RS P20201514 A RSP20201514 A RS P20201514A RS 61193 B1 RS61193 B1 RS 61193B1
- Authority
- RS
- Serbia
- Prior art keywords
- salt
- mor
- preparation
- crystal form
- opioid receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710242119 | 2017-04-14 | ||
| PCT/CN2018/082935 WO2018188643A1 (zh) | 2017-04-14 | 2018-04-13 | 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 |
| EP18784878.3A EP3610875B1 (en) | 2017-04-14 | 2018-04-13 | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61193B1 true RS61193B1 (sr) | 2021-01-29 |
Family
ID=63792318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201514A RS61193B1 (sr) | 2017-04-14 | 2018-04-13 | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11014914B2 (sr) |
| EP (1) | EP3610875B1 (sr) |
| JP (1) | JP7153030B6 (sr) |
| KR (1) | KR20190140962A (sr) |
| CN (1) | CN110049980B (sr) |
| AU (1) | AU2018251119B2 (sr) |
| BR (1) | BR112019021447A2 (sr) |
| CA (1) | CA3057383A1 (sr) |
| CY (1) | CY1124063T1 (sr) |
| DK (1) | DK3610875T3 (sr) |
| ES (1) | ES2828636T3 (sr) |
| HR (1) | HRP20210022T1 (sr) |
| HU (1) | HUE053244T2 (sr) |
| LT (1) | LT3610875T (sr) |
| MX (1) | MX2019012251A (sr) |
| MY (1) | MY196571A (sr) |
| PL (1) | PL3610875T3 (sr) |
| PT (1) | PT3610875T (sr) |
| RS (1) | RS61193B1 (sr) |
| SI (1) | SI3610875T1 (sr) |
| TW (1) | TWI682929B (sr) |
| UA (1) | UA124400C2 (sr) |
| WO (1) | WO2018188643A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61193B1 (sr) * | 2017-04-14 | 2021-01-29 | Jiangsu hengrui medicine co ltd | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
| KR20190133047A (ko) * | 2017-04-14 | 2019-11-29 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도 |
| CN111836807A (zh) * | 2018-04-28 | 2020-10-27 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
| WO2020073985A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| WO2020073984A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| KR20210113824A (ko) | 2020-03-09 | 2021-09-17 | 건국대학교 산학협력단 | 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물 |
| KR20240032999A (ko) * | 2021-07-13 | 2024-03-12 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | Mor 수용체 작용제의 약학적으로 허용 가능한 염, 이의 다형체 및 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02754B (me) | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| PT3354649T (pt) | 2015-10-15 | 2020-02-03 | Jiangsu Hengrui Medicine Co | Derivado oxa espiro, seu método de preparação e suas aplicações em medicamentos |
| RS61193B1 (sr) * | 2017-04-14 | 2021-01-29 | Jiangsu hengrui medicine co ltd | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
-
2018
- 2018-04-13 RS RS20201514A patent/RS61193B1/sr unknown
- 2018-04-13 PL PL18784878T patent/PL3610875T3/pl unknown
- 2018-04-13 CN CN201880004976.2A patent/CN110049980B/zh active Active
- 2018-04-13 UA UAA201911049A patent/UA124400C2/uk unknown
- 2018-04-13 HU HUE18784878A patent/HUE053244T2/hu unknown
- 2018-04-13 BR BR112019021447A patent/BR112019021447A2/pt active Search and Examination
- 2018-04-13 AU AU2018251119A patent/AU2018251119B2/en active Active
- 2018-04-13 US US16/499,453 patent/US11014914B2/en active Active
- 2018-04-13 SI SI201830176T patent/SI3610875T1/sl unknown
- 2018-04-13 KR KR1020197033496A patent/KR20190140962A/ko active IP Right Grant
- 2018-04-13 JP JP2019555801A patent/JP7153030B6/ja active Active
- 2018-04-13 WO PCT/CN2018/082935 patent/WO2018188643A1/zh active Application Filing
- 2018-04-13 EP EP18784878.3A patent/EP3610875B1/en active Active
- 2018-04-13 LT LTEP18784878.3T patent/LT3610875T/lt unknown
- 2018-04-13 MX MX2019012251A patent/MX2019012251A/es unknown
- 2018-04-13 TW TW107112721A patent/TWI682929B/zh active
- 2018-04-13 CA CA3057383A patent/CA3057383A1/en active Pending
- 2018-04-13 PT PT187848783T patent/PT3610875T/pt unknown
- 2018-04-13 DK DK18784878.3T patent/DK3610875T3/da active
- 2018-04-13 ES ES18784878T patent/ES2828636T3/es active Active
-
2019
- 2019-10-03 MY MYPI2019005849A patent/MY196571A/en unknown
-
2020
- 2020-10-22 CY CY20201101000T patent/CY1124063T1/el unknown
-
2021
- 2021-01-07 HR HRP20210022TT patent/HRP20210022T1/hr unknown
- 2021-01-07 US US17/143,549 patent/US20210130332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3610875T3 (da) | 2020-12-21 |
| RU2019136088A (ru) | 2021-05-14 |
| EP3610875A1 (en) | 2020-02-19 |
| US20210130332A1 (en) | 2021-05-06 |
| TW201837033A (zh) | 2018-10-16 |
| WO2018188643A1 (zh) | 2018-10-18 |
| BR112019021447A2 (pt) | 2020-05-05 |
| US20200048229A1 (en) | 2020-02-13 |
| KR20190140962A (ko) | 2019-12-20 |
| JP7153030B6 (ja) | 2023-07-24 |
| AU2018251119A1 (en) | 2019-11-07 |
| PT3610875T (pt) | 2020-11-25 |
| SI3610875T1 (sl) | 2021-02-26 |
| HRP20210022T1 (hr) | 2021-03-05 |
| UA124400C2 (uk) | 2021-09-08 |
| EP3610875A4 (en) | 2020-02-19 |
| CA3057383A1 (en) | 2018-10-18 |
| AU2018251119B2 (en) | 2021-07-29 |
| LT3610875T (lt) | 2020-11-25 |
| CN110049980A (zh) | 2019-07-23 |
| PL3610875T3 (pl) | 2021-04-19 |
| TWI682929B (zh) | 2020-01-21 |
| ES2828636T3 (es) | 2021-05-27 |
| HUE053244T2 (hu) | 2021-06-28 |
| JP2020516642A (ja) | 2020-06-11 |
| MX2019012251A (es) | 2019-11-28 |
| CY1124063T1 (el) | 2022-03-24 |
| CN110049980B (zh) | 2020-10-20 |
| EP3610875B1 (en) | 2020-10-07 |
| JP7153030B2 (ja) | 2022-10-13 |
| MY196571A (en) | 2023-04-19 |
| RU2019136088A3 (sr) | 2021-06-16 |
| US11014914B2 (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3610875T (lt) | Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas | |
| IL283362A (en) | A thrbeta receptor agonist compound and a method for its preparation and use | |
| IL287166A (en) | A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor | |
| HK1259170A1 (zh) | 一種tlr7激動劑的晶型a、其製備方法和用途 | |
| EP3675837A4 (en) | LOW TEMPERATURE STABLE OPIOID ANTAGONIST SOLUTIONS | |
| HK1259175A1 (zh) | 一種tlr7激動劑的馬來酸鹽、其晶型c、晶型d、晶型e及其製備方法和用途 | |
| HK1259182A1 (zh) | 一種tlr7激動劑的三氟乙酸鹽、晶型b、製備方法和用途 | |
| RS61773B1 (sr) | Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe | |
| EP3305316A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SARCOPENIA COMPRISING A PEPTIDE-1 RECEPTOR AGONIST SIMILAR TO GLUCAGON | |
| EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
| PT3216791T (pt) | Substância polimórfica de cloridrato de yonkenafil, método de preparação e composição e uso da mesma | |
| HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
| EP3336088A4 (en) | CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | |
| EP3461823A4 (en) | PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF | |
| ME03062B (me) | Nova sol ivabradina sol i postupak njegove pripreme | |
| HUE047148T2 (hu) | MET receptor antagonista proteinek | |
| PT3303297T (pt) | Novo método para a preparação de base de ivabradina de elevada pureza e sais da mesma | |
| ZA201504398B (en) | Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof |